Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at ACR Convergence 2026. The presentations will showcase clinical data for FT819, including administration without conditioning chemotherapy and outpatient administration capabilities, as well as updates on the Phase 1/2 COMPLETE Trial for FT839, a dual-CAR T-cell candidate targeting CD19 and CD38 for autoimmune diseases.